Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready
Eberhard-Karls-Universität Tübingen Medizinische Fakultät currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, DRISCOLL, MAUREEN VARINA, and is located within 1 distinct art unit. The focus of the current prosecution is therefore limited to a single technical and administrative channel. This concentration in 1 distinct art unit ensures that the technical review is conducted within a specific specialized group in the Biotechnology & Pharmaceuticals sector.
The busiest examiner, DRISCOLL, MAUREEN VARINA, is responsible for 1 pending office action, which constitutes the entirety of the company's 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the applicant faces a streamlined examination process. This alignment between the pending action and the examiner simplifies the management of the portfolio. The presence of 1 distinct examiner ensures that the applicant has a single point of contact for the current filing. This structure minimizes the complexity of managing multiple pending office actions across different units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 1 (12%) |
| Multi-statute (no §101) | 6 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UNDERDAHL, THANE E | 1 | 58.8% | +50.8% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| KERN, ASHLEIGH LAUREN | 1 | 32.7% | +8.4% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
| 17890222 | MEDICAL DEVICE AND METHOD FOR GENERATING A PLASMA-ACTIVATED LIQUID | KERN, ASHLEIGH LAUREN | — |
| 17671407 | Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy | BELLAH, JEFFREY LAWRENCE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1672 | 1 |
| 1636 | 1 |
| 1671 | 1 |
| 1644 | 1 |
| 3794 | 1 |
| 1600 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | 1699 | §102§103§112 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | 1672 | §103 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | 1636 | §103§112Other | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | BLUMEL, BENJAMIN P | 1671 | §102§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17890222 | MEDICAL DEVICE AND METHOD FOR GENERATING A PLASMA-ACTIVATED LIQUID | KERN, ASHLEIGH LAUREN | 3794 | §102§103 | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17671407 | Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy | BELLAH, JEFFREY LAWRENCE | 1600 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 1656 | §103§112 | Non-Final OA | 36d overdue | Pending | Oct 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial